

Express Mail No.: EV 531 712 384 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Reed et al (as amended)	Confirmation No.: 5470
Application No.: 10/823,253	Group Art Unit: 1644
Filed: April 12, 2004	Examiner: Rinaudo, Jo Ann S.
For: RECOMBINANT IL-9 ANTIBODIES AND USES THEREOF	Attorney Docket No.: 10271-112-999

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. §1.56 AND §1.97

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure imposed by 37 C.F.R. § 1.56 and § 1.97 to inform the Patent Office of all references coming to the attention of each individual associated with the filing or prosecution of the subject application, which are or may be material to the patentability of any claim of the application, Attorneys for Applicants hereby invite the Examiner's attention to the references **A54**, **B14** to **B16**, and **C11** to **C37** listed on the attached revised form PTO 1449 entitled "List of References Cited by Applicant." Copies of references, **B14** to **B16**, and **C11** to **C37** are submitted herewith. Pursuant to 37 C.F.R. § 1.98(a)(2)(i), a copy of the cited U.S. patent (*i.e.*, A54) is not submitted herewith.

Identification of the listed references is not meant to be construed as an admission of Applicants or Attorneys for Applicants that such references are available as "prior art" against the subject application.

Applicants respectfully request that the Examiner review the foregoing references and that the references be made of record in the file history of the application.

Pursuant to 37 C.F.R. § 1.97(c), Applicants estimate that a \$180 fee is due in connection with the filing of this Information Disclosure Statement. Please charge the necessary fee to Jones Day Deposit Account No. 50-3013. A duplicate of this sheet is enclosed for accounting purposes.

Respectfully submitted,

Date May 1, 2006

Margaret B. Brivanlou 40,922
Margaret B. Brivanlou (Reg. No.)

JONES DAY
222 East 41st Street
New York, New York 10017-6702
(212) 326-3939

Enclosures

By : Jennifer J. Chheda
Reg No. 46,617

LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	ATTY. DOCKET NO. 10271-112-999	APPLICATION NO. 10/823,253
	APPLICANT Reed et al.	
	FILING DATE April 12, 2004	ART UNIT 1644

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	PAGES, COLUMNS, LINES, WHERE RELEVANT PASSAGES OR RELEVANT FIGURES APPEAR
	A54	6,005,079	12/21/99	Casterman et al.	

FOREIGN PATENT DOCUMENTS

		FOREIGN PATENT DOCUMENT COUNTRY CODE, NUMBER, KIND CODE (IF KNOWN)	DATE	NAME	PAGES, COLUMNS, LINES, WHERE RELEVANT PASSAGES OR RELEVANT FIGURES APPEAR	T
	B14	WO 94/04678	03/03/94	Casterman et al.		
	B15	WO 94/25591	11/10/94	Unilever NV		
	B16	WO 01/44301	06/21/04	Unilever NV		

NON PATENT LITERATURE DOCUMENTS

Examiner Initials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	T
	C11	BORREBAECK & CARLSSON, 2001, "Human therapeutics antibodies." Curr. Opin. in Pharm. 1:404-408.	
	C12	CHOWDHURY & WU., 2005, "Tailor- made antibody Therapeutics." Methods 36:11-24	
	C13	CLACKSON et al., 1991, "Making antibody fragments using phage display libraries." Nature 352:624-628	
	C14	DALL'ACQUA et al., 1996, "A Mutational Analysis of the Binding of Two different proteins to the same antibody," Biochem 35:9667-9676	
	C15	DALL'ACQUA et al., 2005, "Antibody Humanization by framework shuffling" Methods 36:43-60.	
	C16	DAVIES & RIECHMANN, 1995, "Antibody VH Domains as a Small Recognition Units." Biotechnol. 13:475-479	
	C17	DUMOULIN et al., 2002, "Single-domain antibody fragments with high conformational stability." Protein Sci.11:500-515.	
	C18	HOLT, 2003, "Domain antibodies: proteins for therapy." Trends in Biotech. 21(11):484-490	
	C19	KLIMKA et al., 2000, "Human anti-CD30 recombinant antibodies by guided phage antibody selection using cell panning." Brit. J. of Canc. 83(2):252-260	
	C20	KOBAYASHI et al., 1997, "Analysis of Assembly of Synthetic Antibody Fragments: Expression of Functional scFV with Predefined Specificity." Biotechniques 23:500-503	
	C21	MALMBORG et al., 1995, "BIAcore as a tool in antibody engineering." J. of Immunol. Methods. 183:7-13	
	C22	MARKS et al., 1992, "By-Passing Immunization: Building High Affinity Human Antibodies by Chain Shuffling." Biotechnol. 10:779-783	
	C23	MUYLDERMANS, 2001, "Single domain camel antibodies: current status." J. Biotechnol. 74(4):277-302	
	C24	NUTTAL et al., 2000, "Immunoglobulin VH domains and beyond: design and selection of single-domain binding and targeting reagents." Curr. Pharm. Biotechnol. 1(3):253-263	
	C25	OHLIN & BORREBAECK, 1998, "Insertions and deletions in hypervariable loops of antibody heavy chains contribute to molecular diversity." Molec. Immunol. 35:233-238	
	C26	PEREIRA et al., 1998, "Cardiolipin Binding a Light Chain from Lupus-Prone Mice." Biochem. 37:1430-1437	
	C27	RADER et al., 1998, "A phage display approach for rapid antibody humanization: Designed combinatorial V gene libraries." Proc. Natl. Acad. Sci. USA 95:8910-8915	
	C28	RIECHMANN et al., 1999, "Single domain antibodies: comparison of camel VH and camelised human VH domains." J. Immuno. Methods 231:25-38	
	C29	SODERLIND et al., 1995, "Domain libraries: Synthetic diversity for de novo design of antibody V-regions."	

LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	ATTY. DOCKET NO. 10271-112-999	APPLICATION NO. 10/823,253
	APPLICANT Reed et al.	
	FILING DATE April 12, 2004	ART UNIT 1644

NON PATENT LITERATURE DOCUMENTS

Examiner Initials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	T
		Gene 160:269-272.	
	C30	SODERLIND et al., 2001, "The Immune Diversity in a Test Tube - Non-Immunised Antibody Libraries and Functional Variability in Defined Protein Scaffolds." <i>Combinator. Chem. & High Through. Screen.</i> 4:409-416	
	C31	TSUMOTO et al., 2002, "Inhibition of hepatitis C virus NS3 protease by peptides derived from complementarity-determining regions (CDRs) of the monoclonal antibody 8D4: tolerance of a CDR peptide to conformational changes of a target." <i>FEBS Letters</i> 525:77-82	
	C32	VAN DEN BEUCKEN et al., 2001, "Building Novel Binding Ligands to B7.1 and B7.2 Based on Human Antibody Single Variable Light Chain Domains." <i>J. Mol. Biol.</i> 310:591-601	
	C33	WARD et al., 1989, "Binding activities of a repertoire of single immunoglobulin variable domains secreted from <i>Escherichia coli</i> ." <i>Nature</i> 341:544-546	
	C34	WATKINS et al., 2004, "Molecular studies of anti-HLA-A2 using light chain shuffling: a structural model for HLA antibody binding." <i>Tiss. Antigens</i> 63:345-354	
	C35	WU et al., 1998, "Stepwise <i>in vitro</i> affinity maturation of Vitaxin, an $\alpha\beta_3$ -specific humanized mAb	
	C36	WU, "Simultaneous humanization and affinity Optimization of Monoclonal Antibodies." <i>Method. ion Molec. Bio.</i> 207:197-212	
	C37	YANG et al., 1995, "CDR walking mutagenesis for the Affinity maturation of a potent Human Anit-HIV-1 Antibody into the picomolar range." <i>J. Mol. Biol.</i> 254:392-403	

EXAMINER	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	